Inhibrx Biosciences INBX
NASDAQ INBX
$92.18 +1.57 (+1.73%)
As of: Nov 11, 2026 · 9:30 AM EST

Inhibrx Biosciences (INBX) Cash from Financing Activities (2023 - 2026)

Updated

Inhibrx Biosciences' Cash from Financing Activities was $1.25 million in Q4 2025, up 256.3% from the prior quarter.

Analysis

Inhibrx Biosciences (INBX) Cash from Financing Activities (2023 - 2026) Analysis & Trends

For FY2025, Cash from Financing Activities at Inhibrx Biosciences came in at $101.45 million, up 41.5% from FY2024.

  • In earlier years, Cash from Financing Activities was $71.68 million in FY2024 (-64.5%) and $201.96 million in FY2023.
  • Quarterly Cash from Financing Activities has moved between $352,000 (Q3 2025) and $199.89 million (Q3 2023) over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -7.22 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -8.53 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 6.82 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -2.43 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 6.63 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -4.39 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -1.53 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -2.51 Bn
10 Inhibrx Biosciences 1.33 Bn 760.41 Mn - 1.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.60 Mn
Mar 31, 2026 75.46 Mn
Dec 31, 2025 1.25 Mn
Sep 30, 2025 352,000.00
Mar 31, 2025 99.84 Mn
Jun 30, 2024 32.95 Mn
Mar 31, 2024 38.73 Mn
Dec 31, 2023 860,000.00
Sep 30, 2023 199.89 Mn
API Access

Inhibrx Biosciences Cash from Financing Activities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=INBX&period=max&api_key=YOUR_API_KEY